Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Enigma Biomedical Group signs license agreement with Merck for novel MK-6884 imaging agent

DOSIsoft PLANET Onco Dose receives FDA clearance for molecular imaging & molecular radiotherapy dosimetry

Improving molecular imaging using a deep learning approach

Nuclear medicine imaging monitors effectiveness of therapy for melanoma patients

Vect-Horus and RadioMedix announce signing of a letter of intent to co-develop a radio-theranostic agent for Glioblastoma

Siemens Healthineers announces first U.S. installation of Biograph Vision PET/CT system in Philadelphia

RWTH Aachen’s ExMI Institute expands molecular imaging capabilities with MILabs’ Integrated Optical/CT system

PET scans show biomarkers could spare some breast cancer patients from chemotherapy

Cerveau Technologies and Institut de Radiofarmacia Aplicada de Barcelona to manufacture investigational tau ligand, [18F]MK-6240

Novel PET/CT imaging agent shows promise for safe and effective diagnosis of acute venous thromboembolism

Phoenix delivers first production accelerator to SHINE

Press releases may be edited for formatting or style
Janesville, WI – SHINE Medical Technologies Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, and Phoenix LLC, manufacturer of the world's strongest compact neutron generators, announced today that Phoenix has delivered the first production accelerator to SHINE's Building One, the first building on the SHINE medical isotope production campus in Janesville, WI.

Known as the first production unit, this state-of-the-art accelerator system was designed and built by Phoenix specifically for the SHINE medical isotope project, which will produce radioisotopes used in medical imaging. Previous Phoenix prototype systems demonstrated the neutron output and up-time required for medical isotope production in the SHINE facility. The first production unit is the third-generation design for SHINE and is the first system designed for regular commercial use.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510

"This is a really special day for all of us, and is personally very exciting for me," said SHINE CEO, Greg Piefer. "This delivery represents the culmination of almost a decade of joint work between Phoenix and SHINE, moving from proof of concept, to proof of scale, and now to a commercial-ready unit that can produce thousands of doses of medicine per day when paired with the SHINE target. Our tests in Building One will prove the technology is ready for production and provide us important maintenance and operational data well in advance of starting up the actual plant."

"Phoenix's mission is to tackle humanity's greatest challenges with nuclear technology," said Ross Radel, Phoenix CEO. "We're incredibly excited to see all the hard work over the years result in this outcome. Through our partnership with SHINE, our neutron generators will support production of enough Mo-99 to provide millions of people a year with the critical imaging procedures they need."

The first production unit was delivered to SHINE's Building One on Monday, October 15th, 2018. After installation and commissioning, it will allow SHINE to gain operating experience, train employees, and develop maintenance procedures prior to construction of its commercial production facility. Construction of the SHINE medical isotope production facility is slated to begin in the spring of 2019. Once built, the production facility will contain eight independent isotope production units, each with its own Phoenix neutron generator. At full capacity, the SHINE facility will be able to supply over one third of global demand for Mo-99. Commercial production of Mo-99 will begin in 2021.
  Pages: 1 - 2 >>

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.